Beda Pharmaceuticals
Innovative drug development targeting major diseases like cancer and diabetes with significant R&D investment.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
N/A | Series A | ||
| Total Funding | 000k | ||
Related Content
Betta Pharma is a pharmaceutical company focused on the research and development of innovative drugs aimed at treating major diseases such as malignant neoplasms (cancers) and diabetes. The company operates in the biomedical sector and serves a global market, including healthcare providers, hospitals, and patients. Betta Pharma's business model revolves around substantial investment in R&D, with expenditures reaching 590 million yuan in 2018, 680 million yuan in 2019, and 740 million yuan in 2020. This investment supports over 30 innovative drug projects, 18 clinical trials, and four ongoing Phase III clinical trials, including the global multi-center Nshateni project. The company also fosters innovation through its Biomedical Entrepreneurship Innovation Platform, known as the Bedda Dream Workshop, which helps scientists turn their innovative ideas into reality. Betta Pharma generates revenue through the development and commercialization of its proprietary drugs, licensing agreements, and partnerships with other pharmaceutical companies.
Keywords: innovative drugs, cancer treatment, diabetes treatment, R&D investment, clinical trials, biomedical sector, healthcare providers, global market, entrepreneurship platform, pharmaceutical partnerships.
